SAN DIEGO, Jan. 26, 2016 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced that Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen will present at the 2016 Immunotherapy World Forum (IWF), to be held Jan. 25-27 in Washington, D.C.
Details of the presentation:
Title: Retroviral Replicating Viruses as Agents for Anticancer Immunotherapy
Date: Wednesday, Jan. 27
Time: 9:25-9:45 a.m. ET
Tocagen is a clinical-stage, cancer-selective immunotherapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. For more information visit www.tocagen.com or follow @Tocagen.
SOURCE Tocagen Inc.